On June 30, 2025, the U.S. Food and Drug Administration ("FDA") issued an alert on a potential signal of serious risks associated with argenx's Vyvgart Hytrulo product, stating that the treatment has a potential risk of "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy" based on reports to the FDA Adverse Event Reporting System. The alert also said that the "FDA is evaluating the need for regulatory action." On this news, argenx's American Depositary Share ("ADS") price fell $8. ...